Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

Periodontal Infection May Determine Best Treatment for Patients with RA

Lara C. Pullen, PhD  |  July 4, 2016

Past research has indicated that a periodontal pathogen that produces the peptidularginine deiminase (PPAD) enzyme may affect levels of anti-cyclic citrullinated peptide antibody. A new study suggests serum anti-PPAD IgG titers might be a useful biomarker for designing a personalized treatment strategy for RA…

Arthritis Prevalence on the Rise, Creating Challenges for Healthcare System

Arthritis & Rheumatology  |  June 28, 2016

Updated projections suggest that arthritis and arthritis-attributable activity limitation will remain large and growing problems for clinical and public health systems, which must plan and create policies and resources to address these future needs. By 2040, the number of U.S. adults with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million. Can the healthcare system accommodate these projected increases? Not without changes. By 2025, the expected demand for rheumatologists is expected to exceed supply by 2,576 adult and 33 pediatric rheumatologists…

Opinion: Erosive Changes Questioned in RA/Lupus Overlap Syndrome

George A.W. Bruyn, MD, PhD  |  June 13, 2016

I read with interest the Diagnostic View (TR, April), which, according to the authors, represented a case of rhupus, an overlap syndrome of RA and SLE. I challenge this view. My arguments: In the case of erosive RA, typically erosive changes are seen at MTP joints other than MTP1 (e.g., MTP5). In addition, the erosive…

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome

Reuters Staff  |  June 12, 2016

NEW YORK (Reuters Health)—Disease remission in patients with rheumatoid arthritis (RA) is associated with a lower risk of developing metabolic syndrome, according to a new study from Thailand. Researchers also found that a lower educational level was linked to a higher risk of metabolic syndrome, they report in Joint Bone Spine, online May 26. Dr….

Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Lara C. Pullen, PhD  |  June 6, 2016

New research confirms that patients with rheumatoid arthritis who respond to treatment experience an increase in cholesterol levels, including total cholesterol, LDL-C and HDL-C levels. However, the use of triple therapy may be important for understanding this association and mitigating its risk…

Baricitinib Has Promising Clinical Trial Results for Treating RA

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2016

Recent clinical trials have shown that baricitinib is safe and effective for treating patients with rheumatoid arthritis who have proved non-responsive to multiple biologic treatments…

Antibodies Can Spot RA in the General Population

Reuters Staff  |  May 9, 2016

NEW YORK (Reuters Health)—Anti-citrullinated protein antibodies (ACPA), particularly high anti-CCP2 titers, can diagnose rheumatoid arthritis (RA) in the general population with a high degree of accuracy, a Swedish study suggests. ACPA are highly specific for RA, but until now the diagnostic accuracy of ACPA in the general population has not been “thoroughly assessed,” note Dr….

Triple Therapy with Methotrexate Effective, Cheaper in RA

Larry Hand  |  April 27, 2016

NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…

Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

Neha Ohri, MD, & Kristine A. Kuhn, MD, PhD  |  April 15, 2016

The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 74
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences